Symbols

COGT

Cogent Biosciences·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

Significant Net Income Decline

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About COGT

Cogent Biosciences, Inc.

A biotechnology company that focused on developing novel precision immunotherapies to treat cancer

Industry

Pharmaceutical

Established Date

Listing Date

03/29/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

258

Fiscal Year Ends

12-31

Website

www.cogentbio.com

Security Type

Common stock

Office address

275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451

Business

Introduction

Cogent Biosciences, Inc., was incorporated in March 2014 under the laws of the State of Delaware. The company is a clinical-stage biotechnology company focused on developing precision therapies for hereditary diseases. The company's approach is to design reasonable precision therapies that treat the root causes of disease and improve the lives of patients. The company's most advanced project is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor designed to effectively inhibit KIT D816V mutations and other mutations in KIT exon 17.

Company Financials

EPS

COGT has released its 2025 Q4 earnings. EPS was reported at -0.6, versus the expected -0.51, missing expectations. The chart below visualizes how COGT has performed over recent quarters, highlighting trends in earnings surprises.